AVEO Pharmaceuticals, Inc. (AVEO)
| Market Cap | 219.74M |
| Revenue (ttm) | 6.02M |
| Net Income (ttm) | -35.58M |
| Shares Out | 21.40M |
| EPS (ttm) | -1.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $6.43 |
| Previous Close | $6.63 |
| Change ($) | -0.20 |
| Change (%) | -3.02% |
| Day's Open | 6.68 |
| Day's Range | 6.35 - 6.73 |
| Day's Volume | 805,367 |
| 52-Week Range | 4.07 - 18.24 |
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report first quarter 2021 financial results on ...
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company's B...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA® (tivozanib) a...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes the ful...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 6,000,000 shares of its common stock at a price to the p...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. In connection with the offering, AVEO...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that FOTIVDA® (tivozanib) is now commercially available in the United States (U.S.) ahead of the previous March 31, 2021 guidance. O...
AVEO (AVEO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
AVEO (AVEO) delivered earnings and revenue surprises of -15.79% and -70.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the full year ended December 31, 2020 and provided a business update. “The U.S. Food and Drug Administration's ...
AVEO forges an alliance with Bristol Myers to evaluate Fotivda in combination with Opdivo for RCC.
AVEO Pharmaceuticals Inc's (NASDAQ: AVEO) brief positive news of getting FDA approval for Tivozanib in relapsed kidney cancer this month was upset after its partner CANbridge Life Sciences voluntarily t...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it will regain its rights to AV-203 outside of North America, its clinical-stage potent humanized IgG1 monoclonal antibody that...
AVEO Pharmaceuticals Inc (NASDAQ: AVEO) has entered into a collaboration and supply agreement with Bristol-Myers Squibb Co (NYSE: BMY) to evaluate the former's Fotivda (tivozanib) in combination with th...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate FOTIVDA® (tivozan...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules...
One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.
Aveo Pharmaceuticals Inc. (NASDAQ: AVEO) shares are trading higher Thursday after the company received FDA approval for Fotivda for the treatment of adult patients with relapsed or refractory advanced r...
The FDA has finally approved AVEO Pharmaceuticals Inc's (NASDAQ: AVEO) tivozanib for advanced renal cell carcinoma, nine years after it first submitted its marketing application to the agency. The label...
AVEO (AVEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer. Mr. Ferraresso will be responsible for managing AVEO's commercial str...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved FOTIVDA® (tivozanib) for the treatment of adults with relapsed or refr...
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C. Wainwright Global Life Sciences Confere...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in a fireside chat at the 2021 SVB Leerink Glob...
BOSTON, Mass.--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the presentation of two analyses of the Company's pivotal TIVO-3 study, its Phase 3 trial comparing tivozanib, AVEO's next-ge...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) an...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA®), AVEO's vas...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today highlighted its recent progress and outlined its 2021 outlook. “We remain keenly focused on building out our commercial team ahead of the pote...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences: H...
AVEO Oncology Announces Webcast of Presentation at the 39th Annual J.P. Morgan Healthcare Conference
BOSTON, Mass.--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the 39th Annual J.P. Morgan Healthcare Co...
AVEO is preparing for the potential U.S. commercial launch for Tivozanib in R/R RCC. The FDA has set the PDUFA Date for March 31st, 2021.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on...
AVEO (AVEO) delivered earnings and revenue surprises of -37.50% and -5.39%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the third quarter ended September 30, 2020 and provided a business update. “In advance of the Food and Drug Adm...
BOSTON & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced that previously reported results from the Phase 1b/2 TiNivo study of oral (PO) tivozanib,...
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. In this role, Mr. Crist will be responsible for building out AVEO's sales...
AVEO Pharmaceuticals (AVEO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology. TIVO-3 is the...
As of late, it has definitely been a great time to be an investor AVEO Pharmaceuticals.
AVEO reclaims complete rights to ficlatuzumab from Biodesix for an undisclosed sum. The candidate is being developed for several cancer indications.
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock?
AVEO Pharmaceuticals (AVEO) seeks an FDA nod for Fotivda in the United States to treat relapsed or refractory RCC. A decision from the regulatory agency is expected on Mar 31, 2021.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has regained full global rights to ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody which bind...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences: B...
AVEO (AVEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.
About AVEO
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a pote... [Read more...]
| Industry Biotechnology | IPO Date Mar 12, 2010 |
| CEO Michael Bailey | Employees 49 |
| Stock Exchange NASDAQ | Ticker Symbol AVEO |
Analyst Forecasts
According to 4 analysts, the average rating for AVEO stock is "Strong Buy." The 12-month stock price forecast is 22.75, which is an increase of 253.81% from the latest price.